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Abstract
Background: The clinical data of plasma NVP level, safety and efficacy of antiretroviral therapy
(ART) for the concurrent use of nevirapine (NVP)-based ART and fluconazole (FLU) is scanty.
Methods: A retrospective study was conducted in patients who were initiated NVP-based ART
between October 2004 and November 2005. The objectives were to compare NVP levels, adverse
events, and 36-week efficacy of NVP-based ART between patients who did not receive FLU (group
A) and those who received FLU 200 mg/day or 400 mg/day (group B).
Results: There were 122 patients with mean ± SD age of 36 ± 9 years; 81 in group A and 41 in
group B. Median (IQR) baseline CD4 cell count was 29 (8–79) cell/mm3 in group A and 19 (8–33)
cell/mm3 in group B (P = 0.102). Baseline characteristics between the two groups were similar.
Mean ± SD NVP levels were 6.5 ± 3.0 mg/L in group A and 11.4 ± 6.1 mg/L in group B(P < 0.001).
One (2.4%) patient in group B developed clinical hepatitis (P = 0.336). Six (7.4%) patients in group
A developed NVP-related skin rashes (P = 0.096). There were no differences in term of 36-week
antiviral efficacy between the two groups (P > 0.05).
Conclusion: Co-administration of NVP and daily dosage of FLU (200 mg/day and 400 mg/day)
results in markedly increased trough plasma NVP level when compared to the administration of
NVP alone. The concurrent use of NVP and FLU in very advanced HIV-infected patients is well-
tolerated. The immunological and virological responses are favorable.
Background
Cryptococcal meningitis has been a leading cause of mor-
tality and morbidity among AIDS patients particularly in
developing countries [1]. Before the era of combined
active antiretroviral therapy (ART), approximately 5%–
8% of HIV-infected patients in developed countries
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acquired cryptococcosis [2]. The incidence has substan-
tially declined after the era of combined effective ART.
However, it is still a major problem in developing coun-
tries [3-5].
Cryptococcal meningitis is a major opportunistic infec-
tion in HIV-infected patients, especially those who had
CD4 count of less than 100 cells/mm3 [4,6]. Current
guidelines recommend the use of high dose of amphoter-
icin B 0.7–1.0 mg/kg/day combined with flucytosine 100
mg/kg/day during the first two weeks of treatment. After
successful induction therapy, amphotericin B and flucyto-
sine can be discontinued and consolidation therapy with
fluconazole (FLU) 400 mg/day for a minimum of eight
weeks is recommended [7]. After completion of 10-week
treatment, FLU 200 mg/day has been used for standard
secondary prophylaxis until immune reconstitution
occurs as a consequence of ART [7-10]. In addition, FLU is
also the preferred azole drug for systemic treatment of
candidiasis and coccidioidomycosis [11].
Regarding ART, nevirapine (NVP)-based ART is an alterna-
tive non-nucleoside reverse transcriptase inhibitor
(NNRTI)-based ART [12,13]. The potential adverse events
of NVP including skin rashes and hepatotoxicity that gen-
erally occur within the first six weeks are well described
[14,15]. The Thai Government Pharmaceutical Organiza-
tion has produced a fixed-dose combination of stavudine
(d4T) 30 or 40 mg, lamivudine (3TC) 150 mg, and NVP
200 mg (GPO-VIR), which has been available on the mar-
ket since 2002. This new combination formula makes
simple dosing feasible by taking one tablet twice daily.
The previous study of bio-equivalence showed that NVP
concentrations were within international and manufac-
turer's standard [16]. The majority of HIV-infected
patients in Thailand have received this combined pill due
to more affordable cost [17-19].
Nonetheless, the potential drug-drug interaction between
NVP and FLU is a major concern. NVP induces cyto-
chrome P450 isoenzymes in the liver while FLU inhibit
the activity of this enzyme [20-22]. A previous report has
demonstrated that fluconazole significantly raises plasma
NVP levels and may cause serious hepatotoxicity [23].
Conversely, NVP does not significantly influence the
plasma level of FLU. However, there have not been
enough data or any recommendations to adjust NVP dos-
age for the concurrent use of both drugs in order to avoid
the adverse events. There is little clinical data of safety and
tolerability for concurrent use of NVP and FLU. We there-
fore conducted this retrospective study to compare the
trough plasma NVP levels and frequencies of adverse
events among antiretroviral HIV-infected patients who
did not receive FLU and received FLU for cryptococcosis
prophylaxis or treatment and concurrently received NVP-
based ART regimens.
Methods
A retrospective study was conducted among antiretroviral-
naïve HIV-infected patients who were initiated NVP-based
ART with a fixed-dose combination of d4T, 3TC and NVP
200 mg (GPO-VIR) between October 2004 and Novem-
ber 2005 at Bamrasnaradura Infectious Diseases Institute,
Ministry of Public Health, Nonthaburi, Thailand. The
clinical data were retrospectively reviewed and retrieved
from case records. Inclusion criteria were as follows: (1)
HIV-infected patients >15 years of age, (2) naïve to
antiretroviral therapy, (3) were initiated with a NVP-based
ART regimen, (4) used NVP 200-mg once-daily lead-in
dose during the first 2 weeks, prior to escalation to 200 mg
twice daily i.e. patients received a fixed-dose combination
tablet in the morning time and then received separate tab-
let of d4T and 3TC in the evening at 12 hours apart.
The patients were excluded if baseline creatinine level was
higher than 2.0 mg/ml; baseline liver aminotransferase
enzyme was higher than five times of upper normal limit,
or receiving a medication that has drug-drug interactions
with NVP or FLU, or FLU dosage was changed during the
first six weeks of antiretroviral treatment. Each eligible
patient was categorized into one of the two groups accord-
ing to whether the patient received FLU or not as follows:
did not receive FLU (group A) or received FLU 200 mg/
day or 400 mg/day (group B). The trough plasma NVP lev-
els were performed after six weeks of NVP-based ART. All
patients in group B did not have the dosages of FLU
changed before measurement of NVP level. Liver enzymes
were monitored at 12 weeks of ART and when patients
developed clinical signs and symptoms suggested for clin-
ical hepatitis.
Regarding treatment of cryptococcosis, patients received
an 8-week induction of FLU 400 mg/day after 2-week
amphotericin B; and followed with FLU 200 mg/day for
maintenance treatment. The patients in group B who were
initiated NVP-based ART while receiving 400 mg/day had
trough plasma NVP levels performed before FLU dose
reduction. The others who were initiated NVP-ART while
receiving FLU 200 mg/day had received both drug
through the end of the study. All patients were followed
for 36 weeks after initiating NVP-based ART.
The primary objective was to compare the mean trough
plasma NVP levels between the two groups. The second-
ary objectives of interest were as follows: 1) to compare
the frequencies of clinical hepatitis, skin rashes and ele-
vated liver function test including alkaline phosphatase
(ALP), aspatate aminotransferase (AST), alanine ami-
notransferase (ALT) and total bilirubin at three monthsBMC Infectious Diseases 2007, 7:14 http://www.biomedcentral.com/1471-2334/7/14
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after initiation of NVP-based ART and 2) to compare
immunological and virological response between the two
groups.
Blood samples for NVP level were obtained 12 hours (by
patients observed taking dosing) after drug administra-
tion to analyze NVP levels at the HIV Netherlands-Aus-
tralia-Thailand (HIV-NAT) Research Pharmacokinetic
Laboratory located at Chulalongkorn Medical Research
Center (Chula MRC) by high performance liquid chroma-
tography (HPLC) assay. The assay was developed in
Department of Clinical Pharmacology at the University
Medical Centre Nijmegen, the Netherlands. The HPLC
system consisted of a model P4000 solvent delivery
pump, a model AS3000 autosampler, a model UV2000
programmable UV detector wavelength 251 nm and the
computing integrator for HPLC model SN4000 system.
The units were all from Thermo Finnigan (San Jose, Cali-
fornia, U.S.A.). The analytic column was an Omnisher 5
C18 column (150 × 4.6 mm ID; particle size, 5 μm) pro-
tected by a Chromguard RP column – both of which were
from Varian (Middelburg, The Netherlands). Analytic col-
umn runs were processed by Millennium32 software from
Water (Etten-Luer, The Netherlands). The NVP retention
time was 1.8 minutes. The NVP calibration curve was lin-
ear over a range of 0.055 to 15.700 mg/l. The lower limit
of quantification for NVP was 0.05 mg/l. Recovery after
extraction from plasma was 101.8 ± 4.6%. Accuracy in
plasma ranged from 102% at 0.083 mg/L, 101% at 0.829
mg/l and 103% at 4.149 mg/l (n = 15). Within-day preci-
sions ranged from 6.40% at 0.083 mg/l, 4.97% AT 0.830
mg/l and 2.69% at 4.149 mg/l. Between-day precisions
ranged from 3.65% at 0.083 mg/l, 0% at 0.830 mg/L and
0% at 4.149 mg/l.
Mean (± standard deviation, SD), median (interquartile
range, IQR) and frequencies (%) were used to describe
patients' characteristics in each treatment groups. Chi-
square test and Mann-Whitney test were used to compare
categorical and continuous variables respectively between
the two treatment groups. Paired T-test was used to com-
pare liver function test between baseline and three
months after initiating NVP. All analyses were performed
using SPSS program version 11.5. A P value less than 0.05
was considered statistically significant. The study was
approved by the ethical review board of the institute.
Results
There were 199 patients who were initiated NVP-based
ART during the period of study. Among these patients, 72
cases and 5 cases were excluded from the study due to
receiving medications that have drug-drug interactions
and having high baseline liver transaminase enzymes,
respectively. A total of 122 patients with a mean ± SD age
of 36 ± 9 years and 55% male were eligible and included
in the study. Of 122 patients, 81 and 41 patients were clas-
sified into group A and B, respectively. The patients' base-
line characteristics between the two groups are shown in
Table 1. Baseline characteristics including age, gender,
body weight, serum ALP, AST, ALT, total bilirubin, CD4
cell counts and plasma HIV RNA between the two groups
were not different. All patients received the same back-
bone antiretroviral drugs including stavudine and lamivu-
dine.
The distributions of trough plasma NVP levels are shown
in Figure 1. Mean ± SD NVP levels were 6.5 ± 3.0 and 11.4
± 6.1 mg/l in group A and B, respectively (P < 0.001). Of
41 patients in group B, 14 patients were receiving FLU 200
mg/day and 27 patients were receiving FLU 400 mg/day
when NVP levels were performed. Mean trough NVP level
was 9.8 ± 4.3 mg/l in the patients receiving FLU 200 mg/
day and 12.2 ± 6.8 mg/l in the patients receiving FLU 400
mg/day (P = 0.255). Mean trough plasma NVP level in
group A was also significantly lower than that in each sub-
set of group B patients (P < 0.001).
Seventy patients in group A (6 [7.4%] rash, 3 [3.6%] died,
2 [2.4 %] lost to follow-up) and 33 patients in group B (4
[9.7%] died, 3 [7.3%] lost to follow-up, 1 [2.4%] hepati-
tis) continue to follow-up until 36 weeks of ART. There
was a higher tendency of drug discontinuation from all
causes in group B (P = 0.073). The causes of death among
7 patients were not related to the adverse events. All causes
of death were related to opportunistic infections or HIV
infection, including cerebral toxoplasmosis, Mycobacte-
rium avium complex infection, CMV radiculomyelitis, sep-
sis and wasting syndrome.
CD4 cell count and plasma HIV RNA were not performed
in 7 patients (3 in group A and 4 patients in group B).
Therefore, 67 patients in group A and 29 patients in group
B were evaluated for virological and immunological
response by on-treatment analysis. After 36 weeks of ART,
61 of 67 (91.04%) patients in group A and 26 of 29
(89.66%) in group B achieved undetectable plasma HIV
RNA (P = 0.549). Group A patients had median CD4 cell
counts of 104, 152 and 192 cells/mm3 at week 12, 24 and
36, respectively. Group B patients had median CD4 cell
counts of 94, 119 and 161 cells/mm3 at the corresponding
periods. There was no difference of CD4 change from
week 0 to week 36 between the two groups (P = 0.869).
Median (IQR) CD4 cell count changes at 36 weeks from
baseline were 155 ± 95 cells/mm3 in group A and 152 ±
134 cells/mm3 in group B (P = 0.869).
Liver enzymes at 12 weeks of ART between the two groups
are shown in Table 2. The patients in group A had higher
level of serum ALP than the patients in group B (P =
0.011). There were no differences of AST, ALT and totalBMC Infectious Diseases 2007, 7:14 http://www.biomedcentral.com/1471-2334/7/14
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bilirubin between the two groups (P > 0.05). By repeated
measurement analysis, ALP and ALT levels after 12 weeks
of NVP-based ART were not different from baseline in
both groups (P > 0.05). The frequencies of adverse events
including clinical hepatitis and skin rashes are shown in
Table 2. Six of 81 (7.4%) patients in group A developed
skin rashes in which all events occurred within the first 6
weeks of ART; one of 41 (2.4%) patients in group B devel-
oped clinical hepatitis after 5 weeks of ART. Among the
patients who experienced cutaneous reactions, all patients
developed diffuse erythematous maculopapular rashes
grade II and grade III. No patient developed severe skin
reactions such as Stevens Johnson syndrome or toxic epi-
dermal necrolysis. ART in all patients with adverse events
was switched to efavirenz-based ART and they could toler-
ate well.
A 31-year old male in group B who developed clinical
hepatitis had a baseline CD4 cell count of 17 cells/mm3
and plasma NVP level of 10.2 mg/l. He developed symp-
Table 1: Baseline characteristics between the two study groups
Demographics Group A (n = 81) Group B (n = 41) p value
Age, years, mean ± SD 37 ± 9 35 ± 8 0.310
Male gender 44 (54.3%) 23 (56.1%) 1.000
Body weight, kgs, mean ± SD 54.1 ± 10.3 50.8 ± 9.9 0.095
Baseline CD4 counts, cell/μl, 
median (IQR)
29 (8–79) 19 (8–33) 0.102
Baseline plasma HIV RNA, copies/
ml, median (IQR)
271,500 (95,353–714,000) 201,000 (73,125–688,500) 0.269
Baseline ALP, U/l, median (IQR) 85.5 (65.8–126.3) 93.0 (66.0–141.0) 0.565
Baseline AST, U/l, median (IQR) 34.0 (25.3–47.8) 34.0 (21.0–54.0) 0.636
Baseline ALT, U/l, median (IQR) 32.5 (22.0–48.3) 28.5 (13.8–52.3) 0.225
Baseline total bilirubin, mg/dl, 
median (IQR)
0.5 (0.4–0.7) 0.6 (0.3–0.8) 0.561
ALP = alkaline phosphatase, AST = aspatate aminotransferase, ALT = alanine aminotransferase
The distribution of trough plasma NVP levels among the study groups Figure 1
The distribution of trough plasma NVP levels among the study groups.
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toms of nausea and vomiting after five weeks of NVP.
Liver function test showed combined cholestasis and
hepatotoxicity. The other potential causes of hepatitis
were excluded. Serology of hepatitis B virus and hepatitis
C virus were negative. NVP, d4T and 3TC were discontin-
ued; clinical symptoms and liver function test results turn
to be normal within three weeks. d4T, lamivudine and
efavirenz were then prescribed. He could tolerate this sec-
ond regimen well.
Discussions and conclusion
In the present study, we demonstrate that co-administra-
tion of NVP and daily dosage of FLU (200 mg/day and
400 mg/day) results in markedly increased trough plasma
NVP level when compared to the administration of NVP
alone. From the MEDLINE database, the present study is
the first study to date documenting plasma NVP levels
among advanced HIV-infected patients who concurrently
received NVP and FLU versus those who did not received
FLU.
As we know that cryptococcosis occurs in advanced HIV-
infected patients who are vulnerable to other opportunis-
tic infections. ART should not be delayed when cryptococ-
cal diseases are improved. NVP-based ART is most
affordable ART regimen in resource-limiting countries.
Some physicians may somewhat reluctant to initiate NVP-
based ART while the patients are receiving FLU for treat-
ment or prophylaxis of cryptococcosis. Deference of ART
may increase the risk of disease progression and interven-
ing opportunistic infections. From these reasons, we
attempted to determine the plasma NVP levels and
adverse events while the patients were concurrently receiv-
ing FLU.
The plasma half-life of either FLU or NVP are approxi-
mately 30 hours after oral administration [11]. The steady
state of metabolism of both drugs had been achieved
when plasma NVP levels were measured. The timing
period of exposure to both NVP and FLU in all patients in
group B was at least six weeks. This period is enough to
evaluate not only steady state of plasma NVP levels but
also the frequency of adverse events. The results show that
plasma NVP levels among patients in group B (11.6 mg/l)
were approximately 76% higher than the plasma NVP
level in group A (6.6 mg/l). Currently, the recommended
optimal trough plasma NVP levels should be higher than
3.4 mg/l [13]. Our data corresponds to the previous study
that conducted in stable African HIV-infected patients on
ART with an average CD4 cell count of 375 cell/mm3 who
received FLU 200 mg/day [23]. Seventy percents of
patients in this previous study were female. Herein, we
demonstrate the actual situation of common concomitant
use of NVP and FLU in advanced HIV-infected patients.
Geel and colleagues demonstrated that trough plasma
NVP level was 9.4 mg/l in patients concurrently received
NVP and FLU 200 mg/day. However, the plasma NVP
level in our patients who received FLU 200 mg/day was
comparable to the result from this previous study [23]. In
addition, the present study also demonstrated that mean
trough plasma NVP levels were not different between
patients receiving daily 200 and 400 mg. One reason that
may explain this could be that FLU 200 mg/day maxi-
mally inhibit enzyme that metabolizes NVP. Thus, drug-
drug interaction between NVP and FLU may have a ceiling
effect. However, the power of sample size may not enough
to detect this difference.
Liver toxicity is an important complication among HIV-
infected patients who receive NVP-based ART. This drug
can increase potential for liver toxicity through either
hypersensitivity reaction during the early period of ART or
dose-dependent effect [24]. The results from the present
study showed that there was no difference of clinical hep-
atitis or elevated liver function test between the two
groups. This finding corresponds to a previous large retro-
spective study which demonstrated the safety of co-
administration of NVP and FLU [25]. However, one
patient (2.4%) in group B developed clinical hepatitis at
five weeks after NVP-based ART. Both NVP and FLU are
potential causes of hepatitis. However, there have been
rare cases of serious hepatic reactions from FLU [26,27].
Table 2: Liver enzymes and adverse events after 12 weeks of ART
Parameters Group A (n = 81) Group B (n = 41) p value
Liver enzymes
ALP at week 12, U/l, median (IQR) 81.5 (65.0–116.8) 77.0 (112.0–132.5) 0.011
AST at week 12, U/l, median (IQR) 20.3 (25.0–33.8) 22.0 (27.5–44.3) 0.351
ALT at week 12, U/l, median (IQR) 17.0 (25.0–38.8) 22.0 (26.0–46.0) 0.329
TB at week 12, mg/dl, median 
(IQR)
0.3 (0.4–0.5) 0.3 (0.4–0.5) 0.907
Adverse events
Skin rashes 6 (7.4%) 0 (0%) 0.096
Clinical hepatitis 0 (0%)* 1 (2.4%) 0.336
* add 0.5 to calculate p valueBMC Infectious Diseases 2007, 7:14 http://www.biomedcentral.com/1471-2334/7/14
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In this patient, only NVP-based ART was discontinued
and then the liver function test had returned to be normal
within three weeks. This may presume that the clinical
hepatitis in this patient was caused by NVP.
A previous study indicated that when the higher plasma
NVP level is achieved, the higher frequency of adverse
events occurred [28]. However, a more recent study dem-
onstrated that plasma NVP level did not have a relation-
ship to adverse events when corrected for known
covariates [29]. The value of periodical drug monitoring
of NVP as a way to prevent toxicity is therefore limited.
Physicians should instead focus on factors that are more
predictive of adverse events including gender, CD4 cell
count and hepatitis coinfection. Geel and colleagues
reported that 8.3% and 16.7% of patients who concur-
rently received NVP and FLU developed clinical hepatitis
and elevated aminotransferase enzymes [23]. The preva-
lence of clinical hepatitis in the present study is markedly
low when compare to this previous report. This discrep-
ancy can be explained by the lower number of CD4 cell
count in the present study and different proportion of
gender. Almost all of patients had CD4 cell counts of less
than 100 cells/mm3. In a published analysis of NVP-asso-
ciated hepatotoxicity, sex-dependent CD4 cell count was
found to be predictive of hepatitis [30]. High CD4 cell
count is a predictor of hepatotoxicity from NVP [14].
Thus, concomitant administration of NVP and FLU shall
not be contraindicated especially among co-infected HIV
and cryptococcus patients since these patients usually
have very low CD4 cell count.
Regarding NVP-associated skin rashes, there was a trend
toward higher prevalence of skin rashes in the patients
who received NVP-based ART alone than another group.
This may be explained by the random variation of the
study. Notably, although the patients in group B had sig-
nificantly higher plasma NVP levels, they had a low rate of
skin rashes. Thus, NVP level is not a predictive factor for
this adverse event that correspond to the previous study
[29]. To date, the mechanism of NVP-associated skin
rashes is still not clear. The patients in group B had a
higher tendency of dead and lost to follow-up but there
were no differences between the two groups. These may be
partly explained by that the patients in group B had more
advanced disease.
Regarding antiviral efficacy, there was no difference in
term of virological outcome between the two treatment
groups after 36 weeks of ART (P = 0.549). In addition,
CD4 cell counts change at week 36 from baseline value
was not different (P = 0.869), CD4 cell count at week 36
was significantly higher than at baseline value (P < 0.001),
Therefore, NVP-based ART showed effective antiviral effi-
cacy among very advanced HIV-infected patients in both
study groups. This result corresponds to the previous stud-
ies that conducted in Thais [17-19].
NVP-based ART is a common regimen which is widely
used for the treatment of HIV-infected patients in
resource-limited countries. Until the other options are
more accessible, NVP-based ART is still a key regimen to
scale up treatment of HIV in resource-limited countries.
The fact remains that many settings in these countries are
still unable to avoid NVP-based ART in advanced co-
infected HIV and cryptococcosis patients. Thus, the exam-
ining of drug-drugs interaction between NVP-based ART
and other drugs widely used in HIV-infected patients is
crucial. In addition to the treatment and prophylaxis of
cryptococcosis, FLU is the preferred azole drug for sys-
temic treatment other common opportunistic infections
in HIV-infected patients, such as esophageal candidiasis,
coccidioidomycosis and alternative treatment of histo-
plasmosis [11]. Our study may provide the safety data of
concomitant use of NVP and FLU for caring HIV-infected
patients.
Some important pharmacokinetic and clinical data were
not evaluated and some selection bias may be occurred
due to the nature of retrospective study. First, plasma NVP
levels were not performed between the first few weeks of
ART while NVP level was not in the steady state. The fre-
quencies of NVP-associated adverse events were at peak
during this period. Second, NVP levels were not per-
formed among the patients who needed to discontinue
NVP during the first few weeks of ART. Third, the propor-
tion of patients who received NVP and daily dose FLU
may not be large enough to detect the difference of rela-
tively low incidence of adverse events and the difference
of plasma NVP levels between the patients who received
FLU 200 mg/day and FLU 400 mg/day. However, our pre-
vious large retrospective study indicated that there was no
difference of clinical hepatitis between patients who
received NVP with FLU 200 mg/day and NVP alone [25].
Forth, the correlation of genetic deposition and plasma
NVP levels was not studied. Fifth, plasma FLU level was
not evaluated. However, NVP does not significantly influ-
ence the plasma level of FLU as mentioned. Sixth, some
patients lost to follow-up and died due to superimposed
opportunistic infections during the study period. Thus,
the final outcomes of these patients are not established.
Lastly, the data may not be applicable for the patient who
has high CD4 cell count and the other ethnic populations.
In conclusion, the frequencies of adverse events during
the early period of concurrent use of NVP and FLU were
comparable with use of NVP without FLU, in spite of sig-
nificantly higher plasma NVP levels at six weeks of ART.
The standard dose of NVP should be safe among advanced
HIV-infected patients receiving FLU. The 36-week virolog-BMC Infectious Diseases 2007, 7:14 http://www.biomedcentral.com/1471-2334/7/14
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ical and immunological responses are not different
between the two groups. The concurrent administration
of NVP and daily dose of FLU in advanced HIV-infected
patient is well-tolerated and efficacious.
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